Journal Article

Extensive cervical lesion and treatment outcomes in women with HIV/HPV co-infection

Taulo, Frank, Chakalisa, Unoda, Wilkin, Timothy, Badal-Faesen, Sharlaa, Godfrey, Catherine, Tiu, Jennifer, Chen, Huichao, Sebitloane, Motshedisi, Mngqibisa, Rosie, Firnhaber, Cynthia, Masheto, Gaerolwe, Samaneka, Wadzanai

2024

Overview

Background Cervical cancer is a common cancer worldwide, with > 85% of deaths occurring in Lower- and Middle-Income Countries where resources for screening programs are limited. Women living with HIV (WLHIV) are at increased risk. HPV test-and-treat is a screening strategy where women with HPV are offered ablative treatment of the cervix to reduce the risk of invasive cancer. WLHIV tend to have more extensive cervical lesions, necessitating more specialised surgical treatments. Method ACTG A5282 was a randomised, open-label, Phase 2 trial conducted in seven countries that compared a cytology-based screening strategy to HPV test-and-treat for cervical cancer prevention in WLHIV. Women with cervical lesions inappropriate for ablative treatment were assigned to Arm C and underwent colposcopy and directed biopsies. Loop electro-excision procedure was performed if high-grade lesions (bHSIL) were present on cervical biopsies. Women were followed 26 weeks later for repeat evaluations. The Clopper-Pearson exact method was used to construct the 95% confidence interval for the proportion of WLHIV with lesions inappropriate for cryotherapy. Logistic regression models were used to assess the factors associated with these lesions. Results Of 1046 women screened, 156 (88%) were Black/Non-Hispanic, with a median age of 36 years; 80% were on ART, and 73% had an HIV-1 RNA < 200 copies/mL. On cervical colposcopy, 17% (179/1046, 95% CI 14.9–19.4%) had cervical lesions inappropriate for cervical ablation. Among 428 (44%) women with High-risk HPV (hrHPV) detected, 112 (26%, 95% CI 22.2%, 30.5%) had cervical lesions inappropriate for ablative therapy. hrHPV was found more commonly among women having lesions inappropriate for ablative therapy as compared to lesions appropriate for ablative therapy (70% vs 54%, p < .001). Among 128 women with extensive cervical lesions undergoing colposcopic biopsies, 43 (34%) had bHSIL detected. Among women undergoing LEEP treatment of bHSIL, 24% had bHSIL detected 26 weeks later. Conclusion Cervical lesions inappropriate for ablative therapy were common among WLHIV. This has implications for cervical cancer programs as these lesions can only be optimally treated with surgical therapies such as loop electroexcision procedures, and the capacity for this procedure should be increased to maximise cervical cancer prevention outcomes.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Ablation / Adult / Antiretroviral therapy / Biopsy / Cancer / Care and treatment / Cellular biology / Cervical cancer / Cervix / Cervix Uteri - pathology / Cervix Uteri - surgery / Cervix Uteri - virology / Clinical trials / Co-infection / Coinfection - virology / Colposcopy / Complications and side effects / Cryotherapy / Cytology / Disease prevention / Female / HIV / HIV care continuum / HIV infection / HIV Infections - complications / HPV / Human immunodeficiency virus / Human papillomavirus / Humans / Infections / Infectious Diseases / Lesions / Medical screening / Medicine / Medicine & Public Health / Middle Aged / Papillomavirus infections / Papillomavirus Infections - complications / Papillomavirus Infections - therapy / Prevention / Regression analysis / Regression models / Risk / Risk factors / Statistical analysis / Strategy / Therapy / Treatment Outcome / Uterine Cervical Dysplasia - epidemiology / Uterine Cervical Dysplasia - surgery / Uterine Cervical Dysplasia - therapy / Uterine Cervical Dysplasia - virology / Uterine Cervical Neoplasms - surgery / Uterine Cervical Neoplasms - therapy / Uterine Cervical Neoplasms - virology / Virology / Women / Womens health